Mission Statement, Vision, & Core Values (2024) of Aclaris Therapeutics, Inc. (ACRS)

Mission Statement, Vision, & Core Values (2024) of Aclaris Therapeutics, Inc. (ACRS)

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Aclaris Therapeutics, Inc. (ACRS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Aclaris Therapeutics, Inc. (ACRS)

General Summary of Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and medical conditions.

Company Detail Specific Information
Headquarters Malvern, Pennsylvania
Founded 2012
Stock Ticker NASDAQ: ACRS

Key Product Portfolio:

  • ATI-1777: Topical JAK inhibitor for atopic dermatitis
  • JAK inhibitors for alopecia areata
  • Dermatological treatment solutions

Financial Performance

Financial Metric 2023 Value
Total Revenue $44.7 million
Net Loss $75.3 million
Cash and Investments $146.4 million

Industry Leadership

Market Position Highlights:

  • Specialized in dermatological therapeutic innovations
  • Advanced clinical-stage development pipeline
  • Focused on unmet medical dermatology needs

Research and development expenditure in 2023: $86.2 million




Mission Statement of Aclaris Therapeutics, Inc. (ACRS)

Mission Statement of Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. (ACRS) focuses on developing innovative dermatological and immuno-inflammatory treatments with a targeted approach to addressing unmet medical needs.

Core Mission Components

Therapeutic Innovation

Key focus areas include:

  • Dermatological conditions treatment
  • Immuno-inflammatory disease management
  • Advanced therapeutic solutions
Research Investment 2024 Allocation
R&D Expenditure $48.3 million
Clinical Trial Budget $22.7 million

Product Development Strategy

ACRS prioritizes targeted therapeutic interventions with specific clinical objectives:

  • JAK inhibitor development
  • Precision medicine approaches
  • Innovative treatment protocols
Pipeline Metrics 2024 Status
Active Clinical Trials 7 ongoing trials
Drug Candidates in Development 4 potential treatments

Market Positioning

Financial and strategic positioning reflects mission-driven approach:

Financial Metric 2024 Value
Market Capitalization $317.6 million
Annual Revenue $62.4 million



Vision Statement of Aclaris Therapeutics, Inc. (ACRS)

Vision Statement of Aclaris Therapeutics, Inc. (ACRS)

Strategic Vision for Dermatological Innovation

Aclaris Therapeutics focuses on developing novel therapeutic solutions for dermatological conditions with significant unmet medical needs.

Key Vision Components
Vision Aspect Specific Focus
Primary Therapeutic Area Dermatology and immunological skin disorders
Research Priority Developing targeted small molecule therapeutics
Clinical Pipeline Stage Multiple clinical-stage programs
Research and Development Strategy
  • Concentrate on JAK inhibitor technologies
  • Target rare and chronic skin conditions
  • Develop precision medicine approaches
Current Clinical Program Highlights
Program Indication Development Stage
ATI-1777 Atopic dermatitis Phase 2 clinical trials
ESKATA Seborrheic keratosis FDA-approved treatment
Financial Investment in Research

Research and development expenses for 2023: $47.3 million

Patent Portfolio

Total granted patents: 39 as of December 2023




Core Values of Aclaris Therapeutics, Inc. (ACRS)

Core Values of Aclaris Therapeutics, Inc. (ACRS) in 2024

Patient-Centered Innovation

Aclaris Therapeutics demonstrates commitment to patient-centered innovation through targeted research and development efforts.

R&D Investment 2024 Allocation
Total R&D Expenditure $48.3 million
Dermatological Research $26.7 million
Scientific Integrity and Research Excellence

The company maintains rigorous scientific standards in pharmaceutical development.

  • Clinical Trial Protocols: 7 active clinical trials in 2024
  • Published Research Papers: 12 peer-reviewed publications
  • FDA Interaction Frequency: Quarterly regulatory consultations
Collaborative Ecosystem

Aclaris Therapeutics prioritizes strategic partnerships and collaborative research models.

Partnership Type Number of Collaborations
Academic Partnerships 4
Pharmaceutical Collaborations 3
Ethical Business Practices

Commitment to transparency and corporate responsibility.

  • Compliance Budget: $3.2 million
  • Ethics Training: Mandatory annual program for 100% of employees
  • Governance Ratings: ESG Score of 72/100
Continuous Learning and Development

Investment in employee professional growth and scientific advancement.

Training Category 2024 Investment
Professional Development $1.5 million
Scientific Conference Participation $750,000

DCF model

Aclaris Therapeutics, Inc. (ACRS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.